MOMI Clinical Core
MOMI 临床核心
基本信息
- 批准号:10420108
- 负责人:
- 金额:$ 47.08万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-04-19 至 2027-03-31
- 项目状态:未结题
- 来源:
- 关键词:2019-nCoVAddressAdvocacyAllogenicBiological Specimen BanksBloodBlood BanksBlood specimenBody mass indexCOVID-19COVID-19 vaccinationCOVID-19 vaccineCatalogsClinicalClinical DataCollectionDataData AnalysesDatabasesDiphtheriaEnrollmentFecesFetal healthFetusFutureGestational AgeGestational DiabetesGoalsGrantHypertensionImmuneImmunityImmunoglobulin GImmunologicsIndividualInfluenzaInfluenza A Virus, H1N1 SubtypeInfluenza vaccinationInfrastructureKnowledgeLeadMaternal HealthMaternal MortalityMaternal antibodyMaternally-Acquired ImmunityMetadataMothersNatural ImmunityNatureParticipantPathogenicityPeripheral Blood Mononuclear CellPertussisPhenotypePlasmaPregnancyPregnancy TrimestersProspective cohortResearchResearch PersonnelRiskSARS-CoV-2 infectionSamplingSpecimenStimulusTetanusTherapeuticThird Pregnancy TrimesterTissue BanksTissue SampleVaccinationVaccinesVirus DiseasesWorkadaptive immune responseadaptive immunitybiobankclinical phenotypeclinically relevantcohortdata managementethnic diversityfetalfluimmune healthlongitudinal analysismaternal morbiditymaternal vaccinationneonatepandemic diseaseplacental transferpregnantprepregnancypreventracial diversitysample collectionseasonal influenza
项目摘要
Clinical Core: Summary
The overall goal of this U19 is to elucidate the pregnancy immunome as it governs maternal and fetal health. A
large gap in knowledge exists regarding innate and adaptive immune responses over the course of pregnancy
and how perturbations in the immunological signature, in each trimester of pregnancy, manifest in attributable
risk to the mother and fetus. An immune paradox exists in pregnancy, as the mother must tolerate a semi-
allogenic fetus while protecting herself and the fetus from pathogenic challenge. Revealing the comprehensive
function of maternal immunity through pregnancy will undoubtedly lead to advanced understanding of maternal
morbidity and mortality from illness such as influenza and COVID-19 and, as such, open new, previously
unrecognized, therapeutic windows. Current therapies to prevent maternal morbidity include vaccinations, which
afford benefit to both the mother and fetus. Yet, our ability to maximize maternal and fetal benefit from
vaccination is limited due to a large gap in knowledge regarding the ever-shifting nature of maternal immunity
across gestation. Maternal vaccination, such as that against influenza, provides enhanced immunity to prevent
maternal morbidity and mortality from seasonal influenza. Maternal vaccination against influenza is universally
recommended for maternal benefit. Fetal benefit from maternal vaccination against influenza is a noted additional
benefit but is not the primary driver of vaccine advocacy among pregnant individuals. In contrast, maternal
vaccination can be employed to have a direct benefit to the fetus in the absence of known benefit to the
mother (e.g. DPT). While maternal vaccination is utilized for both maternal and fetal benefit, the lack of
knowledge regarding immunity during pregnancy, and how it shifts with gestational age and external stimuli (e.g.
viral infection, vaccination), greatly impedes needed advancement in maternal and fetal health. The clinical core
will support all the projects in this proposal though existing biobanks from key investigators, as well as the
acquisition of a new racially and ethnically diverse pregnancy cohort. These unique cohorts will support our
proposal Maternal ‘Omics to Maximize Immunity (MOMi). The core will have two focuses for which there
are tremendous existing gaps in knowledge: 1) to leverage existing longitudinal samples from mothers across
pregnancy with comprehensive biobanking and rigorous clinical phenotyping and 2) to collect longitudinal
samples from pregnant individuals receiving clinically indicated vaccines as “boosts” (e.g. SARS-CoV-2, Flu, and
DPT). These new foci will facilitate the first systematic analyses of longitudinal innate and adaptive immunity in
pregnant individuals and how maternal vaccinations leverage or perturbs pregnant immune health. A continued
focus of the Clinical Core will be to maintain and expand a large bank of blood and tissue samples from pregnant
individuals and to rigorously phenotype all participants, in order to address the impact of clinical variables
associated with immune perturbations (e.g. BMI, hypertensive disorders of pregnancy, diabetes).
临床核心:总结
该 U19 的总体目标是阐明妊娠免疫组,因为它控制着孕产妇和胎儿的健康。一个
关于妊娠期间先天性和适应性免疫反应的知识存在巨大差距
以及在怀孕的每个三个月中免疫学特征的扰动如何表现在归因
对母亲和胎儿的风险。怀孕期间存在免疫悖论,因为母亲必须忍受半免疫
同种异体胎儿,同时保护自己和胎儿免受病原体挑战。全面揭示
怀孕期间母体免疫力的功能无疑会导致对母体的进一步了解
流感和 COVID-19 等疾病的发病率和死亡率,因此,打开了新的、以前的
未被识别的治疗窗口。目前预防孕产妇发病的疗法包括疫苗接种,
对母亲和胎儿都有利。然而,我们有能力最大限度地提高母亲和胎儿的利益
由于对孕产妇免疫力不断变化的性质认识存在巨大差距,疫苗接种受到限制
跨妊娠期。母亲接种疫苗,例如流感疫苗,可以增强免疫力,预防
季节性流感导致的孕产妇发病率和死亡率。母亲普遍接种流感疫苗
推荐用于母亲利益。母亲接种流感疫苗对胎儿的好处是一个值得注意的额外因素
好处,但不是在孕妇中宣传疫苗的主要驱动力。相比之下,母亲
在对胎儿没有已知益处的情况下,可以采用疫苗接种来对胎儿产生直接益处。
母亲(例如 DPT)。虽然孕产妇疫苗接种对孕产妇和胎儿都有好处,但缺乏
有关怀孕期间免疫力的知识,以及免疫力如何随胎龄和外部刺激(例如,怀孕)而变化的知识
病毒感染、疫苗接种),极大地阻碍了孕产妇和胎儿健康所需的进步。临床核心
将通过主要研究人员的现有生物库以及
获得一个新的种族和民族多样化的怀孕队列。这些独特的群体将支持我们
提案“最大化免疫力的母亲组学”(MOMi)。核心将有两个焦点
现有的知识差距是巨大的:1)利用来自不同国家母亲的现有纵向样本
通过全面的生物样本库和严格的临床表型分析来确定妊娠,并 2) 收集纵向数据
接受临床指示疫苗“加强”(例如 SARS-CoV-2、流感和
DPT)。这些新的焦点将有助于对纵向先天免疫和适应性免疫进行首次系统分析。
怀孕个体以及孕产妇疫苗接种如何影响或扰乱怀孕的免疫健康。继续
临床核心的重点将是维护和扩大大量孕妇的血液和组织样本库
个体并对所有参与者进行严格的表型分析,以解决临床变量的影响
与免疫紊乱有关(例如体重指数、妊娠高血压疾病、糖尿病)。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Andrea Goldberg Edlow其他文献
Andrea Goldberg Edlow的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Andrea Goldberg Edlow', 18)}}的其他基金
Research Project 1 - The pregnancy ImmunOME
研究项目 1 - 妊娠 ImmunOME
- 批准号:
10611526 - 财政年份:2022
- 资助金额:
$ 47.08万 - 项目类别:
Cellular models of fetal neurodevelopment in maternal SARS-CoV-2 infection
母体 SARS-CoV-2 感染时胎儿神经发育的细胞模型
- 批准号:
10612535 - 财政年份:2022
- 资助金额:
$ 47.08万 - 项目类别:
Research Project 1 - The pregnancy ImmunOME
研究项目 1 - 妊娠 ImmunOME
- 批准号:
10420109 - 财政年份:2022
- 资助金额:
$ 47.08万 - 项目类别:
Sex Differences in Fetal Brain-Placental Immune Programming in Maternal Obesity
母亲肥胖中胎儿脑胎盘免疫编程的性别差异
- 批准号:
10093233 - 财政年份:2019
- 资助金额:
$ 47.08万 - 项目类别:
Maternal obesity and inflammation as drivers of maternal morbidity in COVID-19
孕产妇肥胖和炎症是 COVID-19 孕产妇发病的驱动因素
- 批准号:
10200505 - 财政年份:2019
- 资助金额:
$ 47.08万 - 项目类别:
Helping Us Grow Stronger (HUGS/Abrazos): COVID-19 in pregnancy and reducing toxic stress in mother-infant dyads
帮助我们变得更强 (HUGS/Abrazos):怀孕期间的 COVID-19 和减少母婴二人的毒性压力
- 批准号:
10393329 - 财政年份:2019
- 资助金额:
$ 47.08万 - 项目类别:
Fetal Brain-Placental Immune Activation in Maternal Obesity
母亲肥胖中胎儿脑胎盘免疫激活
- 批准号:
10229462 - 财政年份:2019
- 资助金额:
$ 47.08万 - 项目类别:
Fetal Brain-Placental Immune Activation in Maternal Obesity
母亲肥胖中胎儿脑胎盘免疫激活
- 批准号:
10002284 - 财政年份:2019
- 资助金额:
$ 47.08万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 47.08万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 47.08万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 47.08万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 47.08万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 47.08万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 47.08万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 47.08万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 47.08万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 47.08万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 47.08万 - 项目类别:
Research Grant














{{item.name}}会员




